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Abstract: The higher death rate caused by COVID-19 in older people, especially those with
comorbidities, is a challenge for biomedical aging research. Here we explore the idea that an
exacerbated inflammatory response, in particular that mediated by IL-6, may drive the deleterious
consequences of the infection. Data shows that other RNA viruses, such as influenza virus, can display
enhanced replication efficiency in senescent cells, suggesting that the accumulation of senescent cells
with aging and age-related diseases may play a role in this phenomenon. However, at present, we
are completely unaware of the response to SARS-CoV and SARS-COV-2 occurring in senescent cells.
We deem that this is a priority area of research because it could lead to the development of several
therapeutic strategies based on senotherapeutics or prevent unsuccessful attempts. Two of these
senotherapeutics, azithromycin and ruxolitinib, are currently undergoing testing for their efficacy in
treating COVID-19. The potential of these strategies is not only for ameliorating the consequences of
the current emergence of SARS-CoV-2, but also for the future emergence of new viruses or mutated
ones for which we are completely unprepared and for which no vaccines are available.
Keywords: cellular senescence; viral infection; inflammation; mitochondria; extracellular vesicles;
senoptotics; senolytics; SASP inhibitors
1. Introduction
The global outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and
the more recent coronavirus 2 (SARS-CoV-2) have made it clear that older people, especially those with
comorbidities, die more easily from these infections than younger people [1–3]. The global spread of
the novel coronavirus disease (COVID-19), and the emerging evidence of a sustained human-to-human
transmission, suggest that we are dealing with a historic challenge to our capacity to protect the health
of our elderly community.
This pandemic requires concerted action in all sectors of public health, but it also poses a challenge
for biomedical aging research. Indeed, understanding the biological mechanisms that are the basis of
the higher susceptibility to death in elderly people may be important to plan preventive and therapeutic
strategies in the current pandemic, as well as for the future emergence of similar pandemic viruses for
which vaccines are unavailable.
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2. Mechanism Driving Inflammation during SARS-CoV-2 Infection
A reduced proportion of lymphocytes and an increased inflammatory response have been observed
in the elderly with the new-type of SARS-CoV-2 pneumonia [4]. The novel coronavirus has been
reported to use the same receptor, angiotensin-converting enzyme 2 (ACE2), used by SARS-CoV, and
spreads mainly through the respiratory tract [5,6]. However, this seems not to be the only target used
by coronavirus to attack human host cells. Glucose regulated protein 78 (GRP78) [7] and furin [8] have
also been identified as membrane proteins that mediate the viral invasion. Once inside cells, the viral
RNAs are detected by the pattern recognition receptors (PRRs) which trigger a downstream cascade of
molecules leading to the activation of the transcription factor nuclear factor-κB (NF-κB) and interferon
regulatory factor 3 (IRF3), with the subsequent production of type I interferons (IFN-α/β) and a series
of pro-inflammatory cytokines [2,9] including interleukin (IL)-1β and IL-6 [10]. The development of an
uncontrolled inflammatory response can thus lead to potentially life-threatening damage to lung tissue.
For this reason, a clinical trial with a monoclonal antibody against the IL-6 receptor (tocilizumab,
also known as atlizumab) has recently started in China in COVID-19 patients (ChiCTR2000029765).
Tocilizumab is an immunosuppressive drug, mainly used for the treatment of rheumatoid arthritis
(RA) and systemic juvenile idiopathic arthritis. Other drugs with similar targeting, such as TZLS-501
(Tiziana Life Science, London, UK) are also in course of development.
Hence, some of the proposed, putative therapies for COVID-19 to limit death in elderly
(comorbid) patients are based on inflammation targets. However, increasing evidence points to
the accumulation of senescent cells in different body tissues as the main source of inflammatory
components during aging and age-related diseases [11]. Using network proximity analyses of drug
targets and CoV–host interactions in the human interactome, additional anti-HCoV repurposable drugs
have been identified [12]. Among them, rapamycin (sirolimus) is a specific inhibitor of mTOR that can
promote autophagy and suppress the secretory phenotype of senescent cells [13]. Another proposed
drug candidate is melatonin which was shown to display similar effects on the senescent secretory
phenotype of lung fibroblasts [14]. A bioinformatic approach supported by artificial intelligence (AI)
has identified ruxolitinib among the potential therapeutics [15]. This is a potent and selective JAK
inhibitor approved for rheumatoid arthritis and myelofibrosis. It has been recently proposed as a
potent suppressor of the secretory phenotype of senescent cells [16,17] and is currently being tested
in at least one clinical trial for COVID-19 (NCT04331665). In contrast, chloroquine, an autophagy
inhibitor, was shown to promote senescence in endothelial cells [18], and is currently undergoing
testing in clinical trials for COVID-19 [19]. Chloroquine or its safer analogue hydroxychloroquine, is
deemed to display enhanced effect when azithromycin is included in the treatment (NCT04322396).
However, another pilot study found no evidence of antiviral clearance or clinical benefits with this
combination [20]. The purpose of the combination of hydroxychloroquine with this antibiotic is
mostly to prevent bacterial superinfection, but recent literature has identified azithromycin among the
compounds (currently named senolytic drugs) which selectively kill senescent cells [21]. Importantly,
it was reported that azithromycin presents more general antiviral effects, as shown for Zika virus [22]
and influenza A(H1N1)pdm09 virus [23]; moreover it is recommended for the treatment of chronic
airways diseases, such as cystic fibrosis [24] and chronic obstructive pulmonary disease [25], in which
cellular senescence has been proposed as a key pathological mechanism [26,27]. Current therapies
proposed for SARS-CoV-2 involving cellular senescence are reported in Table 1.
In light of this evidence from preliminary therapeutic findings, we deem that the interaction of
senescent cells with coronaviruses deserves particular attention in the development of therapies for
SARS-CoV, SARS-CoV-2 and future emerging viruses.
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Table 1. Proposed therapies for COVID-19 targeting senescent cells or their signaling molecules.
Agent Study Related to COVID-19Therapy
Target/Pathways Related to
Cellular Senescence References
Tocilizumab (atlizumab) Clinical trial (ChiCTR2000029765)
Blocker of IL-6R, IL-6 is






and other pilot studies
Azithromycin exerts












Rapamycin Network-based drug repurposingmethodology for HCoV
Inhibitor of mTOR, SASP
suppressor [12,13]
Melatonin Network-based drug repurposingmethodology for HCoV
SASP suppressor in lung
fibroblasts [12,14]
HCoV: Human coronaviruses; IL-6R: Interleukin-6 receptor; mTOR: mammalian target of rapamycin;
SASP: senescence-associated secretory phenotype; JAK: Janus kinases.
3. Cellular Senescence and Inflammatory Response
Cellular senescence entails a multitude of processes which culminate in a state of irreversible cell
cycle arrest in which cells undergo distinctive phenotypic alterations, including profound chromatin
and morphological changes, increased lysosomal activity and levels of tumor-suppressors, including
p53, p16 (Cdkn2a), and p21 (Cdkn1a), as well as significant secretome changes [30]. Cellular senescence
is considered to be an important anti-cancer mechanism as well as a physiological process for tissue
regeneration. However, the excessive accumulation of senescent cells observed in aging and age-related
diseases seems to contribute to chronic inflammation as well as to tissue and organ dysfunction.
Hence, it is reasonable to hypothesize the involvement of cellular senescence in the increased death
rate of COVID-19 among elderly (comorbid) patients. Drugs targeting IL-6 have been included among
the potential strategies to inhibit the deleterious consequences of the senescence-associated secretory
phenotype (SASP), the secretome produced by senescent cells [31,32]. The SASP includes cytokines,
chemokines, proteases, and growth factors, recently collected in a proteomic database [29], which
functionally links the accumulation of senescent cells with its pathological processes [33,34]. However,
the SASP appears to be beneficial or deleterious, depending on the biological context. For example, the
SASP is also responsible for activating an immune surveillance response to remove senescent cells [35].
This response seems to involve macrophages, T-cells as well as NK-cells, and appears to differ in
different tissues. In particular, an orthotopic transplantation model of senescence-inducible tumor
cells in mice has provided evidence that, in contrast to the phenomenon observed in the liver [36],
NK-cells may limit the efficient clearance of senescent cells in the lung [37]. Although this observation
may suggest the hypothesis that senescent cells easily accumulate in aged lungs, understanding the
extent and kind of senescent cell accumulation in aging lung tissue is still a challenge. A recent survey
of senescent cell markers (presence of p16- and p21-positive cells) found an increased number of
p21-positive and p16-positive cells with donor age in skin (epidermis), pancreas, and kidney, but
not in lung [38]. However, senescent fibroblasts, smooth muscle cells, and/or alveolar epithelial cells
have been implicated in the etiology or progression of several human diseases, including chronic
obstructive pulmonary disease, idiopathic pulmonary fibrosis and emphysema [39]. In mice, aging
does not contribute to the induction of cellular senescence by cigarette smoke in the lung of a mouse
model of COPD/emphysema [40], but other studies using aged wild type mice display an increase of
p16Ink4a mRNA and senescence-associated-β-galactosidase (SA-β-Gal) activity in the lung compared
to young controls [41,42]. The stimuli that drive lung cells into senescence are still incompletely
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understood and may include infection or inflammation due to infection. Notably, senescent cells are
not only a source of inflammatory mediators, but they are also carriers of additional damage through a
contagious spreading of senescence and inflammation in neighboring and even distant tissues [43].
The inflammatory components of the SASP are not the only player in this phenomenon. Most recent
evidence has demonstrated that the SASP includes extracellular vesicles (EVs) through which senescent
cells exert central effector functions in the local environment. Senescent cells secrete EVs with a
distinctive, but still incompletely characterized, content of miRNA, proteins, and DNA that can spread
senescence in surrounding and even distant tissues [44–47], thus promoting further inflammation and
catastrophic consequences for the organism [48]. Interestingly, it has been documented that exosomes
are crucial components in the pathogenesis of virus infection, but specific studies for SARS-CoV or
SARS-CoV are still lacking [49].
4. Cellular Senescence and Response to Viruses
Importantly, cellular senescence has been also described as an anti-viral mechanism [50]. Indeed,
the cell cycle arrest and the release of proinflammatory cytokines and chemokines that characterize
cellular senescence are strikingly similar to the features observed by many cells during an antiviral
response. Senescence can also be induced by prolonged signaling of cytokines, such as β-interferon, in
response to viral infection [51] and the SASP can induce senescence in neighboring cells [52] which
have a high probability of being infected. Moreover, many viruses encode inhibitors of programmed
cell death to subvert the host responses during infection [53], suggesting that chronic viral infection
may contribute to the resistance to apoptosis hypothesized for some senescent cells that accumulate
with aging [30]. This hypothesis was also confirmed by the observation that the replication of vesicular
stomatitis virus is impaired both in primary and tumor senescent cells in comparison to non-senescent
cells [54]. Many studies have described a higher prevalence or increased circulating viral load of
some viruses, such as cytomegalovirus (CMV) [55] and Torquetenovirus (TTV) [56,57], with aging.
The increased grade of inflammation associated with this phenomenon and the association with
mortality of TTV and CMV in the elderly highlights the possible involvement of cellular senescence.
In this context, TTV viremia can predict CMV reactivation [58] and a mechanistic link between CMV
and accumulating senescent cells has already been proposed [59]. The CMV serostatus plays also a
prominent role in determining the magnitude of response to influenza vaccination [60].
Some viruses have been shown to induce cellular senescence, such as human immunodeficiency
virus-1 [61], Epstein–Barr virus [62], measles virus [63] and dengue virus [64]. Similar results have
been obtained using the virulence factor, NS1 protein, of the influenza A virus (IFV-A) [65]. Other
viruses have developed mechanisms to overcome senescence and to evade anti-viral response, as
reported for simian virus 40 [66] and human papillomavirus [67]. More recently, it has been shown that
IFV and Varicella Zoster Virus display enhanced replication efficiency in senescent human bronchial
epithelial cells as well as in senescent human dermal fibroblasts compared to non-senescent cells [68].
Coronaviruses are similar to IFVs, in that they both are RNA viruses, but we are completely
unaware of the types of interaction and type of response that SARS-CoV or SARS-CoV-2 can display in
senescent cells. Regarding the molecular targets of SARS-CoV-2 virus, there is no evidence that these
can be upregulated in senescent cells, and some studies may eventually suggest that ACE2 [69] as well
as for GRP78 [70] are downregulated by senescence. However, in few months of studies of COVID-19
pathogenesis, at least four routes of entry have been identified and it is unlikely that the reduced
expression of one or two of these targets may prevent infection of senescent cells. Conversely, it should
be urgently addressed if the results observed for normal IFVs (i.e., that they can induce senescence
and can use senescence to increase their replication rate) can be extended also to SARS-CoV and
SARS-CoV-2. If this is proven to be true, it could be reasonable to hypothesize that the massive presence
of senescent cells in elderly and comorbid patients may exacerbate the mortality rate. The evidence that
patients with cancer, hypertension or with smoking habits (conditions associated with a pathological
role of cellular senescence) experienced worse outcomes from COVID-19 [71], further supports the
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hypothesis that an accumulation of senescent cells may favor the development of severe events during
SARS-CoV-2 infection.
Spreading of senescent cells through the organism is limited by immune surveillance [72–74].
Impaired immune surveillance of senescent cells may contribute to their accumulation during aging [75]
and to the development of cancer [74]. Some component of the SASP contributes to attract and activate
immune cells, thus suggesting that alteration of this process could be particularly important in the
case of viral infection. Age-associated changes in CD4 T-cell functionality have been linked to chronic
inflammation and decreased immunity [76] as well as to senescence immune surveillance [74,77].
Depletion of CD4 T cells resulted in an enhanced immune-mediated interstitial pneumonitis and
delayed clearance of SARS-CoV from the lungs [78].
There are also mechanisms that some viruses have evolved to overcome immune surveillance of
infected cells, for example by targeting mitochondria.
Mitochondria dysfunction in senescent cells can drive important and even specific alterations
of the SASP [79]. When the mitochondrial quality control system is impaired, mitochondria could
release into extracellular space various components (including formyl peptides, mitochondrial DNA,
TFAM, cardiolipin, ATP, succinate and cytochrome C) that could promote or exacerbate SASP; this
phenomenon is named mitochondrial damage-associated molecular patterns (DAMPs) [80]. Many
models of senescent cells are associated with a shift of mitochondria toward more hyperfusion events,
resulting in the presence of abnormally elongated mitochondria [81]. It was also demonstrated that
the reduction in mitochondrial content by mTOR inhibition prevents senescence and attenuates the
SASP [82].
A mechanism based on mitochondria alterations was proposed to explain how SARS-CoV can
escape innate immune surveillance. A protein encoded by SARS-CoV designated as open reading
frame-9b (ORF-9b) localizes to the mitochondria, where it promotes proteasomal degradation of Drp1,
a protein involved in mitochondrial fission [83], leading to mitochondrial hyperfusion [84], which is a
common phenotype of senescent cells and a mechanism involved in resistance to apoptosis [85,86].
The SARS-CoV ORF-9b provides a receptive intracellular environment for viral replication by targeting
the mitochondrial antiviral signaling protein (MAVS) signalosome [84]. During the SARS-CoV infection,
in the presence of ORF-9b, MAVS undergo degradation and this process is accompanied by the loss of
TNF Receptor Associated Factor 3 and 6, two other key signaling intermediaries in antiviral defenses.
This leads to an impairment of the host cell IFN responses [84]. However, silencing of MAVS induces a
general repressive action on NF-κB with the subsequent suppression of IL-6 expression in senescent
cells [87]. This may eventually favor viral replication in the initial phases of the infection without
alerting the immune system. In agreement, a significantly enhanced production of IL-6 is not detected
until day 4 after infection of human lung epithelial cells with SARS-CoV [88]. This could be consistent
with an initial suppression of the mitochondrial antiviral response followed by the later development
of a senescent-like phenotype (Figure 1). Hence, it should be important to verify if SARS-CoV and
SARS-CoV-2 may induce alteration of the SASP in senescent cells through a similar process.
Mitochondrial fusion is generally required for intracellular proliferation of the viruses and
evasion of the antiviral innate immune signaling, as demonstrated for the dengue virus infection
mechanism [89]. In the case of dengue virus infection, cellular senescence seems to exert an anti-viral
function [64] but other viruses, such as IFV, have evolved mechanisms to increase replication in
senescent cells [68]. These observations illustrate that the behavior of different viruses in response to
senescence can be different and that specific studies for each virus are needed.
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Figure 1. Modulation of mitochondrial dynamics upon CoV Infection. ORF-9b, a virulence factor of
severe acute respiratory syndrome coronavirus (SARS-CoV), localizes to mitochondria and causes
mitochondrial elongation by triggering ubiquitination and proteasomal degradation of dynamin-like
protein (DRP1). Further, acting on mitochondria ORF-9b targets the mitochondrial-associated adaptor
molecule MAVS signalosome by usurping poly(C)-binding protein 2 (PCBP2) and the HECT domain
E3 ligase (AID4E3) to trigger the degradation of MAVS. This reduces host cell interferon responses and
antiviral signaling. However, these changes may later trigger cellular senescence and contribute to
enhance the inflammatory response via the senescence associated secretory phenotype (SASP).
5. Therapeutic Perspectives
Clarifying the role of cellular senescence in SARS-CoV infection may additionally provide a strong
rationale for the use of senotherapeutics, such as SASP inhibitors, in the management of elderly patients
affected by COVID-19. Ongoing clinical trials with SASP inhibitors targeting IL-6 as well as with
ruxolitinib (NCT04331665) may provide useful information in this field. This research could eventually
pave the way to exploration of whether other senotherapeutics, such as senolytics (compounds that
selectively kill senescent cells) [90,91], or compounds able to promote clearance of senescent cells by
the immune system [16,92], may eventually provide an additional advantage in the COVID-19 therapy.
Regarding this last aspect, T-cells engineered to express the NKG2D chimeric antigen receptor
(CAR), which recognizes NKG2D ligands on the surface of SCs, may be used to target senescent
cells [16,35]. In turn, the recent discovery of dipeptidyl peptidase 4 (DPP4) as a selective membrane
marker of cellular senescence may provide a target for the development of immune-mediated clearance
of senescent cells [16,93]. However, senescence immune surveillance in the lung may work through
specific and different mechanisms than those reported for other tissues [37]. Hence, addressing this
strategy in the case of infections with a lung target may be very challenging.
In the case of senolytics, it should be also addressed if the mechanism used to kill senescent cells
can favor the release of intact viral particles in the environment. Preliminary results indicating the
efficacy of the senolytic azithromycin in COVID-19 deserve particular attention. In the original paper
describing the senolytic activity of this drug, an effect on mitochondria and mitochondrial oxygen
consumption rate was reported [21], which are well known metabolic targets to induce apoptosis in
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senescent cells [94,95]. Azithromycin can also induce apoptosis by down-regulating Bcl-xL [96], which
is a target of various senolytic compounds including ABT-263, ABT-737 and B1331852 [16]. So far, there
has not been much attention paid to the mechanism of action of senolytics, as the goal of most research
in this area is aimed at removing senescent cells independently from the mechanism of action. Necrosis,
necroptosis, apoptosis and other subcategories of processes leading to cell death play an important and
differential role in the host response to different viral infections [97]. This is an additional challenge,
as it should be carefully evaluated if the mechanism inducing senescent cell death could eventually
favor—or not—the spreading of the virus into neighboring cells. In this context, it might be useful to
employ the recently proposed general term of ‘senocidals’ [90], to identify the pharmaceutical class of
drugs that selectively kills senescent cells, and to discriminate between compounds that selectively
eliminate senescent cells by apoptosis (‘senoptotics’) or by non-apoptotic means (‘senolytics’). In the
case of elderly (comorbid) patients, a clean elimination of infected senescent cells may be critical for the
termination of viral infection without side effects. While this area of research is completely unexplored,
we deem that addressing these aspects could lead to the development of a wide range of therapeutic
strategies to ameliorate the consequences associated with various viral infections.
Another aspect that deserves particular attention is that senotherapeutic molecules have off-target
effects [98] and this is especially true for elderly or comorbid patients, where senotherapy side-effects
due to systemic dosing could actually exacerbate the virally induced disease. Systemic delivery is
currently the only means available for these compounds, for which we have convincing preclinical
data from rodent studies [16]. However, there is a need to develop more-targeted delivery approaches
so that senotherapeutic compounds can reach the senescent cells in the intended tissue site. The recent
development of delivery systems based on encapsulation of diagnostic or therapeutic agents with
β(1,4)-galacto-oligosaccharides and their preferential delivery to lysosomes of senescent cells is a step
forward towards this intent [99]. Notably, this approach was effective in-vivo against pulmonary fibrosis.
The potential therapeutic strategies and the key points that need to be addressed to pave the way
to these strategies are shown in Figure 2. This field of research could be important, not only to cope
with the current SARS-CoV-2 emergency, but also for future emergencies related to new or mutated
viruses for which we are not fully prepared and for which there are no vaccines available.
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Figure 2. A schematic representation of the strategic therapies based on senotherapeutics that may be
useful in the treatment of viral infections. Evidence from ongoing clinical trials point at azithromycin
and ruxolitinib as major candidates in this field. Three aspects that need to be clarified by research
before addressing the proper therapy are highlighted by question marks: (1) Information on the capacity
of the virus to induce senescence and if the virus displays a preference to replicate in non-senescent
versus senescent cells. (2) Understanding if viral replication is suppressed by cellular senescence or if
the virus evolved mechanism(s) to bypass or use senescence to enhance replication. (3) In the case
of strategies based on senocidals, it should be clarified if there are drugs or similar therapies that can
induce cell death without favoring the spreading of the virus to neighboring cells. Selective Bcl-xL
inhibitors and mitochondrial targeted compounds are likely candidates to induce a ‘clean’ apoptosis,
avoiding the spreading of viral particles.
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